Ikena Oncology, Inc. (IKNA)

1.2900 -0.0600 (-4.44%) At close: 04:00PM EDT

Ikena Oncology, Inc.

645 Summer Street
Suite 101
Boston, MA 02210
United States
857 273 8343
https://ikenaoncology.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 43

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Mark Manfredi Ph.D.	President, CEO & Director	810.69k	N/A	1971
Dr. Jotin Marango M.D., Ph.D.	CFO & Head of Corporate Development	577.12k	N/A	1979
Mr. Bob Lally	Senior Vice President of Finance & Operations	N/A	N/A	N/A
Ms. Srividya Subramanian Esq., Ph.D.	VP & Deputy General Counsel	N/A	N/A	N/A
Ms. Samantha Vuksanic	Head of Human Resources	N/A	N/A	N/A
Mr. Jeffrey Ecsedy Ph.D.	Chief Development Officer	N/A	N/A	1970
Mr. Navin Parwani M.S.	VP & Head of Quality	N/A	N/A	N/A
Mr. David Damphousse M.S.	Senior Vice President of Clinical Development Operations	N/A	N/A	N/A
Dr. Caroline Germa M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1972
Mr. Valdas Jurkauskas Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Corporate governance

Ikena Oncology, Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.